To print: Select File and then Print from your browser's menu

Title: Aripiprazole Safe for Schizophrenia or Bipolar 1 Disorder in Adolescents: Presented at CINP

"Aripiprazole Safe for Schizophrenia or Bipolar 1 Disorder in Adolescents: Presented at CINP"

By Bryan DeBusk MUNICH, Germany -- July 17, 2008 -- Treatment with aripiprazole 2 to 30 mg daily for 26 weeks is safe in adolescents with schizophrenia or bipolar 1 disorder, according to research presented here at the 26th Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress. Andrew Forbes, PhD, Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Princeton, New Jersey, presented the results in a poster session on July 14. Investigators evaluated the safety of aripiprazole at a dose of 2 to 30 mg daily for 26 weeks in 281 patients with schizophrenia and in 233 patients with bipolar 1 disorder aged 10 to 17 years in a 6-month, multicentre, open-label, roll-over, flexible-dose study. The cohort consisted of patients with schizophrenia who had previously participated in a 6-week double-blind aripiprazole trial and patients with bipolar 1 disorder who had dropped out of an extension of a 30-week double-blind trial. Six percent of the participants with schizophrenia and 8.6% of the participants with bipolar 1 disorder discontinued the study due to adverse events. Rates of other adverse effects were 23.2% for drowsiness, 21.6% for extrapyramidal effects, 17.7% for headache, and 12.3% for restlessness or akathisia. Although 4 patients reported suicidal ideation, none followed through. Weight changes from normal to abnormal were observed in 19 patients over the course of the study, but mean change in weight z-score was not clinically significant over the course of the study (<0.5 standard deviations). Dr. Forbes noted that the results are consistent with safety data obtained in trials with shorter durations of treatment. Aripiprazole was generally well tolerated over a course of up to 32 weeks, he concluded. Funding for the studies was provided by Otsuka Pharmaceutical Development & Commercialization. [[Presentation title: Long-Term Tolerability and Safety of Aripiprazole in Pediatric Patients With Schizophrenia or Bipolar I Disorder. Abstract P02-05]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.